immunomic therapeutics crunchbase

The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Phone Number +119196161923. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Director of Research and Development at Immunomic Therapeutics, Inc. - most recent Rockville, Maryland, United States. / Oct 13, 2015. ITI-2000 HPV+ Tumors. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). 2016;2016:4857869. This feature is in beta and may change with future updates. ITI maintains its headquarters in Rockville, Maryland. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. -Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Be sure to include your name, the Job Code of the job you are interested in, and the accommodation you are seeking. Melody Carey We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Pancreatic cancer is the fourth-most-common cause of cancer-related mortality in the USA. mcarey@rxir.com The Immunomic Therapeutics, Inc. team includes specialists in the areas of science, process development, engineering, production, marketing, finance, human resources, quality and regulatory, administrative support and more. 2017 Jun 12:1-10. With more than 6 years of experience in the field of cancer metabolism and immunometabolism, ImmunoMet has developed a comprehensive. Types of diversity represented in an organization, specifically of those who are founding members, currently the CEO, or have check-writing abilities in an investment firm. J Biol Chem. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. The UNITE platform can result in a number of downstream effects: CD4+ memory, cytokine production, and a potent antibody response. ITI-1001 GBM - pDNA. Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND) application for ITI-1000 from the University of Florida (UF). This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. ITI-3000 is a plasmid DNA vaccine targeting the large T antigen (LT) of Merkel cell polyomavirus (MCPyV). ITI-1000 GBM - Cell Therapy. Stemming from our UNITE Platform, Immunomic Therapeutics has developed a robust and deep pipeline focused on immunotherapeutics with an emphasis in treating and preventing many oncology indications by leveraging specific characteristics of a type of antigen. In addition, ITI and HLB intend to establish an Asian Brain Cancer Research Center in Seoul that will bring together the worlds leading experts and cutting-edge science to advance research in the GBM field and to deploy ITI-1000 to the Asian population. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. We are based at the Translation & Innovation Hub that sits on Imperial College London's 23-acre White City Campus development in west . Clin Cancer Res 2020;26:5297303, Batich K.A.,Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Founded Date 2015. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. 858-366-3243, Internet Explorer presents a security risk. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. Prior to joining ITI, Ms. Harrison worked as a consultant for various biotechnology companies focused on oncology and infectious disease, leading client interactions with global regulatory authorities regarding product approvals and regulatory planning and implementation. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI") a privately-held clinical-stage biotechnology company pioneering the . The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . The company was founded in 2005 and is based in Lancaster, Pennsylvania. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Hum Vaccin Immunother. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Juniper Point The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. ITI-3000 Merkel Cell Carcinoma - pDNA. 15010 Broschart Road Suite 250. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. ITI-2000 provides an UNITE platform address for HPV+ cancers. The company held a successful pre-IND meeting earlier this year for ITI-1001 and expects to be able to file an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) by the end of 2020. ITI Company: Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). Immunomic Therapeutics Announces Presentation on Nucleic Immunomic Therapeutics Announces the Appointment of Frances Harrison as Senior Vice President, Regulatory Affairs, Northeastern US Biotechnology Female Founded Companies. Katie Pearce. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. We are delighted to welcome Brian to the Immunomic team, said William Hearl, Ph.D., Immunomic Therapeutics Chief Executive Officer. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . Book the hotel with real traveler reviews, ratings and latest pictures of Chinatrust Executive House Hsin-Tien. Active, Closed, Last funding round type (e.g. Evaluate their financials based on Immunomic Therapeutics's post-money valuation and revenue. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. IMU-935, a selective inverse agonist of the transcription factor RORt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barr syndrome. The financing will also enable Immunomic to expand its team and infrastructure to support the future growth of the company. Companies. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. Immunomic Therapeutics' investigational UNITE platform is founded in a combination of complementary technologies and capabilities: ITI's proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Animal Health All. The company believes this approach may harness the bodys immune system to recognize, attack and destroy tumor cells that express CMV, which is over-expressed in GBM. 717-327-1822, ITI Media: 2020 Immunomic Therapeutics, Inc. All Rights Reserved. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. Handled COVID very well. 2017 Aug;47:85-92. Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural . ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Founders Sungwuk Kim. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. Request a free trial. 917-322-2571, Internet Explorer presents a security risk. All content is posted anonymously by employees working at Immunomic Therapeutics. January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that, Vaccine exclusively delivered with the PharmaJet StratisNeedle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet, a company that engineers precision delivery systems that overcome, November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced, October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today. all maps fatal bullet; who is running for senate in maryland 2022 ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. ITI-3000 is being tested in a Phase 1, open label, First in Human (FIH) study to evaluate the safety, tolerability, and immunogenicity of 4 mg of ITI-3000 in patients with Merkel polyomavirus-positive Merkel cell carcinoma (MCC). We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. Jan 30, 2015. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. The primary mechanism of action of ITI-1000 is to generate a T cell-mediated immune response against malignant glial cells expressing the CMV pp65 protein. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. Description. Melissa Kemp Prior to her role at BTG, she held senior regulatory positions at a variety of companies specializing in therapeutics for oncology, respiratory, neurology, regenerative medicine, orthopedics and cardiovascular disease including Life Cell Corporation (Allergan), Alphatec Spine, Covidien (Medtronic), Lumenis LTD, and C.R. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. amy@juniper-point.com Find More Contacts for ImmunoMet Therapeutics, Edit Lists Featuring This Company Section, Dr. Revati Shreeniwas Joins ImmunoMet Therapeutics as Chief Medical Officer, ImmunoMet Therapeutics Appoints Vincent ONeill Chief Medical Officer, Health Care Companies With Less Than $1M in Revenue (Top 10K), Pharmaceutical Companies With Fewer Than 1000 Employees (Top 10K), Southern US Companies With Less Than $50M in Revenue (Top 10K). 301-968-3501 HLB also secured an option to make further investment into the company in the months ahead. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. But a few things must happen first. The company is developing three small molecule products; its lead development program, IMU-838, a selective . ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. Background. In addition, ITI-1001 represents a far more cost-effective approach. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. Bard (Becton, Dickinson and Company). Mitchell D.A.,Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. immunomic therapeutics crunchbase. This is the Immunomic Therapeutics company profile. Melody Carey ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. ITI-ID Candidate Multiple infectious diseases. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. 2003 Sep 26;278(39):37926-36. These factors are currently under intense focus in the cancer immunotherapy landscape. Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms